Kidney Health Initiative Urges Investigators to Include People with Kidney Diseases in Clinical Trials for Coronavirus 2019 (COVID-19) Therapies

American Society of Nephrology (ASN)

 

Highlights:

  • People with kidney diseases are often excluded from clinical trials because of the complexity and high morbidity of kidney disease.
  • COVID-19 puts people with kidney diseases at a two to sixteen-fold increased risk of severe symptoms.
  • All investigators should include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19.

  

Newswise — Washington, DC (June 9, 2020) — Clinical trials often exclude people with kidney diseases. This practice could have significant consequences, if continued, during the Coronavirus – 2019 (COVID-19) pandemic and for the 37 million Americans with kidney diseases who are at high risk of severe disease.

Preliminary studies indicate that people with kidney diseases demonstrate an increased risk (two- to sixteen-fold) for developing severe COVID-19 symptoms. These data support US statistics that show acute kidney injury occurs in up to 5% of hospitalized COVID-19 patients and 50-90% of patients in the intensive care unit. An effective response to the COVID-19 pandemic should include people with kidney diseases.

The KHI Board of Directors considered a variety of issues impacting drug and device development in the kidney community during the COVID-19 pandemic and identified inclusion of people with kidney diseases in clinical trials for COVID-19 therapies as central to improving care. The recent statement, written by members of the Board of Directors is titled “Making the Case for Change: Including People with Kidney Diseases in COVID-19 Trials”.

“Given their increased risk, people with kidney diseases deserve to be prioritized in the development of novel therapies for COVID-19,” said Raymond C. Harris, MD, FASN, Co-Chair of KHI, “KHI urges sponsors and investigators to come alongside the US Food and Drug Administration (FDA) and the patient community to expand their research into this vulnerable population.”

The FDA encourages enrollment practices that lead to clinical trials better reflecting the population most likely to use and benefit from the therapy being studied. This can be achieved through novel trial designs or broadening eligibility criteria, when appropriate, to increase enrollment of underrepresented populations. A recent guidance from the FDA titled “COVID-19: Developing Drugs and Biological Products for Treatment or Prevention” explicitly encouraged sponsors to include people with kidney diseases in their COVID-19 trials.   

As the largest consortia in the kidney community and a public-private partnership between the American Society of Nephrology and the FDA, KHI urges all investigators to include people with kidney diseases when developing vaccines, preventative therapies or treatments related to COVID-19. This population demonstrates increased risk of exposure, infection, and severe morbidity, and inclusion of people with kidney diseases in trials would benefit all aspects of health care.

Individuals who are interested in learning more about KHI, should contact Melissa West, Acting Vice President for Research, Discovery and Innovation, at [email protected]

The Kidney Health Initiative (KHI) is a key part of the newly created ASN Alliance for Kidney Health. KHI is uniquely positioned to realize ASN’s vision of a world without kidney diseases. As a public-private and collaborative partnership with the FDA and more than 100 organizations and companies, KHI catalyzes innovation and the development of safe and effective patient-centered therapies for people living with kidney diseases. Learn more at www.kidneyhealthinitiative.org.

 

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.

 

# # #

 

 




Filters close

Showing results

110 of 5636
Released: 13-May-2021 7:05 PM EDT
FLCCC Statement on the Irregular Actions of Public Health Agencies & the Disinformation Campaign Against Ivermectin
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

FLCCC Alliance calls for whistleblower to step forward from within WHO, the FDA, the NIH, Merck, or Unitaid to counter this misrepresentation

Newswise: shutterstock_1724336896.jpg
Released: 13-May-2021 12:55 PM EDT
Kreuter receives $1.9 million in grants to increase vaccinations in St. Louis
Washington University in St. Louis

Matthew Kreuter, the Kahn Family Professor of Public Health at the Brown School, has received $1.9 million in grants to help increase COVID-19 vaccinations among Blacks in St. Louis City and County.

Released: 13-May-2021 11:35 AM EDT
COVID-19 mRNA Vaccines are Immunogenic in Pregnant and Lactating Women, Including Against Viral Variants
Beth Israel Deaconess Medical Center

In a new study from Beth Israel Deaconess Medical Center researchers evaluated the immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women who received either the Pfizer or Moderna COVID-19 vaccines. They found that both vaccines triggered immune responses in pregnant and lactating women.

Released: 13-May-2021 10:30 AM EDT
Pandemic stigma: Foreigners, doctors wrongly targeted for COVID-19 spread in India
Monash University

The Indian public blamed foreigners, minority groups and doctors for the rapid spread of COVID-19 across the country during the first wave, due to misinformation, rumour and long-held discriminatory beliefs, according to an international study led by Monash University.

Released: 13-May-2021 9:00 AM EDT
28 Community Programs Receive Grants Through Penn Medicine CAREs Program
Perelman School of Medicine at the University of Pennsylvania

Penn Medicine CAREs awarded grants to 28 projects, many of which aim to fill vast needs in the community created by the COVID-19 pandemic, while others seek to improve diversity, equity, and inclusion.

Released: 13-May-2021 9:00 AM EDT
How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET
Newswise

How to Win Over Vaccine Skeptics: Live Expert Panel for May 20, 3pm ET

Released: 13-May-2021 8:00 AM EDT
Dental procedures during pandemic are no riskier than a drink of water
Ohio State University

A new study’s findings dispel the misconception that patients and providers are at high risk of catching COVID-19 at the dentist’s office.

Newswise:Video Embedded lung-damage-not-the-culprit-for-post-covid-exercise-limitations
VIDEO
Released: 13-May-2021 7:00 AM EDT
Lung Damage Not the Culprit for Post-COVID Exercise Limitations
American Physiological Society (APS)

A new study suggests the lungs may not be the main factor that reduce exercise ability in people recovering from severe COVID-19. Anemia and muscle dysfunction also play a role. The study is published ahead of print in the Journal of Applied Physiology. It was chosen as an APSselect article for May.


Showing results

110 of 5636

close
4.77594